Lancashire and South Cumbria
Formulary
Formulary
8 Malignant disease and immunosuppression
The majority of systemic anti-cancer therapies are not listed in this formulary as they are included in either the Lancashire and South Cumbria Cancer Alliance SACT protocols or the Cancer Drugs Fund list, produced by NHSE. |
08-02-03 Anti-lymphocyte monoclonal antibodies
| Alemtuzumab Lemtrada® |
|
Formulary
|
Concentrate for solution for infusion vials 12mg/1.2ml All anti-lymphocyte monoclonal antibodies should be given under the supervision of an experienced specialist, in an environment where full resuscitation facilities are immediately available. |
 MHRA: Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements NICE TA312: Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis |
|
| Ocrelizumab Ocrevus® |
|
Formulary
|
Concentrate for solution for infusion 300mg/10ml All anti-lymphocyte monoclonal antibodies should be given under the supervision of an experienced specialist, in an environment where full resuscitation facilities are immediately available. Only commissioned from a recognised MS Centre with Specialist Nurse support. |
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
|
|
| Ofatumumab Arzerra® |
|
Formulary
|
Concentrate for intravenous infusion 20 mg/mL,5-mL vial ,50-mL vial Only commissioned from a recognised MS Centre with Specialist Nurse support. |
|
MHRA: Ofatumumab▼: reminder of risk of serious and fatal infusion reactions MHRA: Ofatumumab: screen for hepatitis B virus before treatment NICE TA699: Ofatumumab for treating relapsing multiple sclerosis |
|
|
First choice rituximab for new patients.
| Ublituximab Briumvi® |
|
Formulary
|
|
NICE TA1025: Ublituximab for treating relapsing multiple sclerosis |
|
|
Links
- 2013/14 NHS STANDARD CONTRACT
Hepatitis B screen before treatment - Dear Healthcare Provider letter- LSC Breast Chemotherapy Protocols
- MHRA drug Safety Update July 2017: Nivolumab (Opdivo), pembrolizumab (Keytruda): reports of organ transplant rejection
- MHRA Drug Safety Update May 2019: Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements
- MHRA: Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements
- MHRA: Ofatumumab▼: reminder of risk of serious and fatal infusion reactions
- MHRA: Ofatumumab: screen for hepatitis B virus before treatment
- MHRA: Ofatumumab: screen for hepatitis B virus before treatment
- MHRA: Risk of serious and fatal infusion reactions—always give premedication and monitor carefully
- Neuromyelitis optica service - NHS standard contract for 2013/14
- NHSE: National Cancer Drugs Fund list
- NICE guidelines for rituximab
- NICE guidelines for Rituximab
- NICE NG122 : Lung cancer: diagnosis and management
- NICE NG224: Melanoma: assessment and management
- NICE NG47: Haematological cancers: improving outcomes
- NICE NG52: Non-Hodgkin’s lymphoma: diagnosis and management
- NICE TA1025: Ublituximab for treating relapsing multiple sclerosis
- NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
- NICE TA137:Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
- NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia
- NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia
- NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
- NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
- NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA202: Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
- NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
- NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
- NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
- NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
- NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
- NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
- NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
- NICE TA312: Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis
- NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
- NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
- NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
- NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab
- NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
- NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
- NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
- NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
- NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
- NICE TA53: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
- NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
- NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
- NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
- NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
- NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
- NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
- NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
- nice ta589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
- NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
- NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
- NICE TA65: Rituximab for aggressive non-Hodgkin’s lymphoma
- NICE TA65: Rituximab for aggressive non-Hodgkin’s lymphoma
- NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma
- NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
- NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
- NICE TA674: Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)
- NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
- NICE TA683:Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
- NICE TA686:Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
- NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
- NICE TA699: Ofatumumab for treating relapsing multiple sclerosis
- NICE TA699: Ofatumumab for treating relapsing multiple sclerosis
- NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
- NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
- NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
- NICE TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
- NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
- NICE TA772: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies
- NICE TA794 : Diroximel fumarate for treating relapsing–remitting multiple sclerosis
- NICE TA794: Diroximel fumarate for treating relapsing–remitting multiple sclerosis
- NICE TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
- NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
- NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
- NICE TA828:Ozanimod for treating moderately to severely active ulcerative colitis
- NICE TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma
- NICE TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma
- NICE TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma
- NICE TA851 Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer
- NICE TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
- NICE TA892: Mosunetuzumab for treating relapsed or refractory follicular lymphoma
- NICE TA904:Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
- NICE TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
- NICETA513: Obinutuzumab for untreated advanced follicular lymphoma
- Rituximab for ITP-NICE evidence summary